Branko Miladinovic
Overview
Explore the profile of Branko Miladinovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1038
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brookman-May S, Buyse M, Freedland S, Miladinovic B, Zhang K, Fendler W, et al.
Eur Urol
. 2024 May;
86(2):81-87.
PMID: 38762392
Defining meaningful endpoints for research of early-stage high-risk prostate cancer is challenging, with established measures such as overall survival and metastasis-free survival facing limitations related to feasibility and adequate reflection...
2.
Feng F, Miladinovic B, Zhang K, Dignam J, Wang D, Yu M, et al.
Eur Urol
. 2023 Jul;
84(3):331-340.
PMID: 37393115
Background: Early endpoints in clinical trials of high-risk localized prostate cancer (HRLPC) that resemble those monitored in real-world practice could expedite clinical development. Objective: To assess the association of prostate-specific...
3.
Aggarwal R, Alumkal J, Szmulewitz R, Higano C, Bryce A, Lopez-Gitlitz A, et al.
Prostate Cancer
. 2022 Oct;
2022:5454727.
PMID: 36212187
Purpose: This randomized phase 2 study sought to assess the treatment effect of a finite duration of apalutamide with and without androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer...
4.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes A, Chung B, et al.
J Urol
. 2021 Jul;
206(4):923.
PMID: 34296946
No abstract available.
5.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes A, Chung B, et al.
J Urol
. 2021 May;
206(4):914-923.
PMID: 34039013
Purpose: We performed an exploratory analysis of prostate cancer-related pain and fatigue on health-related quality of life in patients with metastatic castration-sensitive prostate cancer receiving apalutamide (240 mg/day) or placebo,...
6.
DeNigris J, Malachowski S, Miladinovic B, Nelson C, Patel N
Cutis
. 2020 Feb;
105(1):E24-E28.
PMID: 32074163
The relationship between physicians and pharmaceutical companies has caused the medical community to question the degree to which pharmaceutical interactions and incentives can influence physicians' prescribing habits. Our study aimed...
7.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes A, Chung B, et al.
Lancet Oncol
. 2019 Oct;
20(11):1518-1530.
PMID: 31578173
Background: In the phase 3 TITAN study, the addition of apalutamide to androgen deprivation therapy (ADT) significantly improved the primary endpoints of overall survival and radiographic progression-free survival in patients...
8.
Jarmi T, Doumit E, Makdisi G, Mhaskar R, Miladinovic B, Wadei H, et al.
Ann Transplant
. 2018 Dec;
23:867-873.
PMID: 30559336
BACKGROUND The effect of pulmonary artery systolic pressure (PASP) measured by Swan-Ganz right heart catheter (SG-RHC) on kidney transplant recipient survival has not been previously studied. The objective of this...
9.
Jarmi T, Patel N, Aslam S, Makdisi G, Doumit E, Mhaskar R, et al.
Ann Transplant
. 2018 Jun;
23:422-426.
PMID: 29915167
BACKGROUND Induction immunosuppression is used in transplantation to prevent early acute rejection. The survival benefit of rabbit anti-thymocyte globulin (rATG) induction has not been established yet. We sought to determine...
10.
Anand A, Sprenker C, Karlnoski R, Norman J, Miladinovic B, Wilburn B, et al.
Scand J Pain
. 2018 Jun;
4(4):249-253.
PMID: 29913919
Background and methods Minimally invasive parathyroidectomy requires limited analgesia and short recovery times. The preferred post-operative analgesic regimen for this patient population has not been established but non-narcotic components would...